Asset Details
Do you wish to reserve the book?
Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer
Do you wish to request the book?
Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer
2017
Overview
Pancreatic ductal adenocarcinoma (PDAC) is almost uniformly fatal; however, some improvement in overall survival has been achieved with the introduction of nanocarriers that deliver irinotecan or paclitaxel. Although it is generally assumed that nanocarriers rely principally on abnormal leaky vasculature for tumor access, a transcytosis transport pathway that is regulated by neuropilin-1 (NRP-1) has recently been reported. NRP-1-mediated transport can be triggered by the cyclic tumor-penetrating peptide iRGD. In a KRAS-induced orthotopic PDAC model, coadministration of iRGD enhanced the uptake of an irinotecan-loaded silicasome carrier that comprises lipid bilayer-coated mesoporous silica nanoparticles (MSNPs); this uptake resulted in enhanced survival and markedly reduced metastasis. Further, ultrastructural imaging of the treated tumors revealed that iRGD coadministration induced a vesicular transport pathway that carried Au-labeled silicacomes from the blood vessel lumen to a perinuclear site within cancer cells. iRGD-mediated enhancement of silicasome uptake was also observed in patient-derived xenografts, commensurate with the level of NRP-1 expression on tumor blood vessels. These results demonstrate that iRGD enhances the efficacy of irinotecan-loaded silicasome-based therapy and may be a suitable adjuvant in nanoparticle-based treatments for PDAC.
Publisher
American Society for Clinical Investigation
Subject
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacokinetics
/ Antineoplastic Agents - pharmacology
/ Camptothecin - analogs & derivatives
/ Camptothecin - pharmacokinetics
/ Carcinoma, Pancreatic Ductal - drug therapy
/ Carcinoma, Pancreatic Ductal - metabolism
/ Carcinoma, Pancreatic Ductal - pathology
/ Humans
/ Methods
/ Mice
/ Nanoparticles - therapeutic use
/ Neoplasms, Experimental - drug therapy
/ Neoplasms, Experimental - metabolism
/ Neoplasms, Experimental - pathology
/ Oligopeptides - pharmacokinetics
/ Oligopeptides - pharmacology
/ Peptides
/ Silicon Dioxide - pharmacokinetics
